RDB04391 - CS-RfA-EG

Resource data sheet
Prev. | Lentiviral vector plasmid >

CS-RfA-EG

Backbone vector of shRNA expressing lentivirus construct by Gateway(R) cloning with GFP marker driven by EF-1 alpha promoter.

Catalog number	RDB04391
Resource name	CS-RfA-EG
Clone info.	Backbone vector of shRNA expressing lentivirus construct by Gateway(R) cloning with GFP marker driven by EF-1 alpha promoter. Use DB3.1 (Invitrogen) or equivalent to amplify this clone. Commonly requested with pENTR4-H1 (RDB04395) for generation of shRNA expression vector and with pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) for packaging. Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Vector backbone	Plasmid
Selectable markers	Amp^r, Cm^r, ccdB (E. coli); Zeo^r (plasmid transfection of mammalian cells).
Originator	Miyoshi, Hiroyuki \|

Lentiviral plasmid list, maps and sequences information. [link]

Distribution information

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe Dr. Hiroyuki Miyoshi (The Developer, the current address: Keio University) as the Developer. Dr. Miyoshi may request the RECIPIENT to report on progress and/or results obtained through the use of the BIOLOGICAL RESOURCE.

Ordering Please visit Ordering instruction.
Order form [Credit Card Payment] [Bank Transfer or Check Payment]
Material Transfer Agreement (MTA) [Word]

Remarks Remember that you will be working with samples containing infectious virus.
Use Survival2 (Invitrogen) or equivalent to amplify this clone.

Distribution information (domestic users) [open/close]

Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe Dr. Hiroyuki Miyoshi (The Developer, the current address: Keio University) as the Developer. Dr. Miyoshi may request the RECIPIENT to report on progress and/or results obtained through the use of the BIOLOGICAL RESOURCE.
Ordering	Please visit Ordering instruction. Order form [Credit Card Payment] [Bank Transfer or Check Payment] Material Transfer Agreement (MTA) [Word]
Remarks	Remember that you will be working with samples containing infectious virus. Use Survival2 (Invitrogen) or equivalent to amplify this clone.

提供条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が三好浩之（現職：慶應義塾大学）により開発されたことを明示する。三好浩之は、利用の状況及び成果等について利用者に報告を求めることができる。
提供依頼	手続きの詳細は、「レンチウイルスベクターの提供申し込み」をご覧ください。提供依頼書 [Word] 提供同意書 [Word] 遺伝子組換え生物の受入れ確認書 [Word]
備考	このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。このクローンの増殖にはSurvival2 (Invitrogen)あるいは同等の宿主を使用してください。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB04391	CS-RfA-EG	DNA solution

Ordering instruction of plasmids [in Japanese] [in English]

References and tips

Electronic file

Electronic file	Sequence RDB04391z.seq from Depositor
Electronic file	PDF (map, protocol and/or remarks) RDB04391.pdf from Depositor

Sequence information

RIKEN BRC has sequenced portions of this material for quality test. Primers and the results are shown below.

Data are summerized on test sheet below.

Test sheet	RDB12134_A5Dhp1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pAxEF_F1	RDB12134_A5Dha.seq
>04391_12134_A5Dh_pAxEF_F1_A01_01.ab1 1 ATTTTTTTCT TCATTTCAGG TGTCGTGAAC ACGCTACCGG TCGCCACCAT GGTGAGCAAG 61 GGCGAGGAGC TGTTCACCGG GGTGGTGCCC ATCCTGGTCG AGCTGGACGG CGACGTAAAC 121 GGCCACAAGT TCAGCGTGTC CGGCGAGGGC GAGGGCGATG CCACCTACGG CAAGCTGACC 181 CTGAAGTTCA TCTGCACCAC CGGCAAGCTG CCCGTGCCCT GGCCCACCCT CGTGACCACC 241 CTGACCTACG GCGTGCAGTG CTTCAGCCGC TACCCCGACC ACATGAAGCA GCACGACTTC 301 TTCAAGTCCG CCATGCCCGA AGGCTACGTC CAGGAGCGCA CCATCTTCTT CAAGGACGAC 361 GGCAACTACA AGACCCGCGC CGAGGTGAAG TTCGAGGGCG ACACCCTGGT GAACCGCATC 421 GAGCTGAAGG GCATCGACTT CAAGGAGGAC GGCAACATCC TGGGGCACAA GCTGGAGTAC 481 AACTACAACA GCCACAACGT CTATATCATG GCCGACAAGC AGAAGAACGG CATCAAGGTG 541 AACTTCAAGA TCCGCCACAA CATCGAGGAC GGCAGCGTGC AGCTCGCCGA CCACTACCAG 601 CAGAACACCC CCATCGGCGA CGGCCCCGTG CTGCTGCCCG ACAACCACTA CCTGAGCACC 661 CAGTCCGCCC TGAGCAAAGA CCCCAACGAG AAGCGCGATC ACATGGTCCT GCTGGAGTTC 721 GTGACCGCCG CCGGGATCAC TCTCGGCATG GACGAGCTGT ACAAGTCCGG ACTCAGATCC 781 TACTAGTAGG ATCTCGAGGG ATCAAGCTTA TCGATAATCA ACCTCTGGAT TACAAAATTT 841 GTGAAAGATT GACTGGTATT CTTAACTATG TTGCTCCTTT TACGCTATGT GGATACGCTG 901 CTTTAATGCC TTTGTATCAT GCTATTGCTT CCCGTATGGC TTTCATTTTC TCCTCCTTGT 961 ATAAATCCTG GTTTGCTGTC TCTTTATGAG GAGTTGTGGC CCGTTGTCAG CAACGTGGCG 1021 TGTGTGCACT GTGTTTGCTG ACGCAACCCC CCCACTGGAT TGGGGGCATT GCACACTGTC 1081 AGCTCGTTTC CAGGAACTTC GCTTCCCTCC CTCCCTATTG ACTACGGCGG GAACTTCAAT 1141 TCGGCCCGG //
Primer: Cm_N_rev	RDB12134_A5Dhb.seq
>04391_12134_A5Dh_Cm_M_R_B01_04.ab1 1 CATGAGGTTA ACTATCCCAT ATCACCAGCT CACCGTCTTT CATTGCCATA CGGAATTCCG 61 GATGAGCATT CATCAGGCGG GCAAGAATGT GAATAAAGGC CGGATAAAAC TTGTGCTTAT 121 TTTTCTTTAC GGTCTTTAAA AAGGCCGTAA TATCCAGCTG AACGGTCTGG TTATAGGTAC 181 ATTGAGCAAC TGACTGAAAT GCCTCAAAAT GTTCTTTACG ATGCCATTGG GATATATCAA 241 CGGTGGTATA TCCAGTGATT TTTTTCTCCA TTTTAGCTTC CTTAGCTCCT GAAAATCTCG 301 ACGGATCCTA ACTCAAAATC CACACATTAT ACGAGCCGGA AGCATAAAGT GTAAAGCCTG 361 GGGTGCCTAA TGCGGCCGCC ATAGTGACTG GATATGTTGT GTTTTACAGT ATTATGTAGT 421 CTGTTTTTTA TGCAAAATCT AATTTAATAT ATTGATATTT ATATCATTTT ACGTTTCTCG 481 TTCAGCTTTT TTGTACAAAC TTGTGATAAT TCAAAGTGAA TTTCTGCTGT CCCTGTAATA 541 AACCCGAAAA TTTTGAATTT TTGTAATTTG TTTTTGTAAT TCTTTAGTTT GTATGTCTGT 601 TGCTATTATG TCTACTATTC TTTCCCCTGC ACTGTACCCC CCAATCCCCC CTTTTCTTTT 661 AAAATTGTGG ATGAATACTG CCATTTGTAG ATCCGTTCAC TAATCGAATG GATCTGTCTC 721 TGTCTCTCTC TCCACCTTCT TCTTCTATTC CTTCGGGCCT GTCGGGTCCC CTCGGGGTTG 781 GGAGGTGGGT CTGAAACGAT AATGGTGAAT ATCCCTGCCT AACTCTATTC ACTATAGAAA 841 GTACAGCAAA AACTATTCTT AAACCTACCA AGCCTCCTAC TATCATTATG AATAATTTTA 901 TATACCACAG CCAATTTGTT ATGTTAAACC AATTCCACAA ACTTGCCCAT TTATCTAATT 961 CCAATAATTC TTGTTCATTC TTTTCTTGCT GGTTTTGCGA TTCTTCAATT AAAGGAGTGT 1021 ATTAAGCTTT GTGTAAATTG TTTAATTTCT CTGTCCCACT CCATCCCAGG GTCGTGTTGA 1081 TTTCTAATCT GTTCCAGAGA TTTTATAACT CGACCTAGCC AATCTAGCAC AGCAGTTGGT 1141 GTGCCCAAAA TGGAGTTTTT TCCGGAGAGA GAC //
Primer: EF1a-N_R	RDB12134_A5Dhc.seq
>04391_12134_A5Dh_EF1a-N_R_C01_07.ab1 1 CCTCTGGGGG ATGTGGGCGA TGTGCGCTCT GCCCACTGAC GGGCACCGGA GCCTCACGAA 61 GCTTGAATTA TCACCACTTT GTACAAGAAA GCTGAACGAG AAACGTAAAA TGATATAAAT 121 ATCAATATAT TAAATTAGAT TTTGCATAAA AAACAGACTA CATAATACTG TAAAACACAA 181 CATATCCAGT CACTATGGTC GACCTGCAGA CTGGCTGTGT ATAAGGGAGC CTGACATTTA 241 TATTCCCCAG AACATCAGGT TAATGGCGTT TTTGATGTCA TTTTCGCGGT GGCTGAGATC 301 AGCCACTTCT TCCCCGATAA CGGAGACCGG CACACTGGCC ATATCGGTGG TCATCATGCG 361 CCAGCTTTCA TCCCCGATAT GCACCACCGG GTAAAGTTCA CGGGAGACTT TATCTGACAG 421 CAGACGTGCA CTGGCCAGGG GGATCACCAT CCGTCGCCCG GGCGTGTCAA TAATATCACT 481 CTGTACATCC ACAAACAGAC GATAACGGCT CTCTCTTTTA TAGGTGTAAA CCTTAAACTG 541 CATTTCACCA GCCCCTGTTC TCGTCAGCAA AAGAGCCGTT CATTTCAATA AACCGGGCGA 601 CCTCAGCCAT CCCTTCCTGA TTTTCCGCTT TCCAGCGTTC GGCACGCAGA CGACGGGCTT 661 CATTCTGCAT GGTTGTGCTT ACCAGACCGG AGATATTGAC ATCATATATG CCTTGAGCAA 721 CTGATAGCTG TCGCTGTCAA CTGTCACTGT AATACGCTGC TTCATAGCAT ACCTCTTTTT 781 GACATACTTC GGGTATACAT ATCAGTATAT ATTCTTATAC CGCAAAAATC AGCGCGCAAA 841 TACGCATACT GTTATCTGGC TTTTAGTAAG CCGGATCCAC GCGTTTACGC CCCGCCCTGC 901 CACTCATCGC AGTACTGTTG TAATTCATTA AGCATTCTGC CGACATGGAA AGCCATCACA 961 AACGGCATGA TGAACCCTGA ATCGCCAGCG GCATCAGCAC CTTGTCGCCT TTGCGTATAT 1021 ATTTGCCCAT GTGAAAACGG GGGCGAGAGT GTCCATATTG CCACGTTTAA TCAAACTGGT 1081 GAACTCACCC AGGATGGCTG AACGAAACAT AATTCTCAAT AAACCTTTAG GAAAATAGGC 1141 CAGG //

Please visit Sequencing and PCR primers for primer information.

References

original	Miyoshi, H., Development of a self-inactivating lentivirus vector. J. Virol., 72 (10): 8150-8157 (1998). PMID 9733856.
user report	Kawasaki, N., TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling Cell Discovery 4 (1): (2018). PMID 29423269.
user report	Yoshitomi, H., Human Sox4 facilitates the development of CXCL13-producing helper T cells in inflammatory environments. Nat. Commun. 9 (1): 3762 (2018). PMID 30232328.
user report	Ishibashi, M., CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Sci. Rep. 7: 46662 (2017). PMID 28429795.
user report	Kobayashi, S., TGF-beta induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur. J. Immunol. 46 (2): 360-371 (2016). PMID 26541894.
user report	Katsura, A., MicroRNA-31 is a positive modulator of endothelial-mesenchymal transition and associated secretory phenotype induced by TGF-beta. Genes Cells 21 (1): 99-116 PMID 26663584.
user report	Neri, S., Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int. J. Cancer. 137 (4): 784-796 (2015). PMID 25648219.
user report	Tanaka, Y., Dual Function of Histone H3 Lysine 36 Methyltransferase ASH1 in Regulation of Hox Gene Expression. PLoS One., 6 (11): e28171 (2011). PMID 22140534.
user report	Ohoka, N., The orphan nuclear receptor RORalpha restrains adipocyte differentiation through a reduction of C/EBPbeta activity and perilipin gene expression. Mol. Endocrinol., 23, 759-771 (2009). PMID 19324970.
user report	Naka, H., Requirement for COUP-TFI and II in the temporal specification of neural stem cells in CNS development. Nat. Neurosci. 11 (9): 1014-1023 (2008). PMID 19160499.
user report	Tsukamoto H., TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4+ T cell clone. Eur. J. Immunol., 36, 1926-1937 (2006). PMID 16791876.

2019.04.18

GNP_filter3_RDBDEP_html_190418.pl